Woodford Patient Capital Share Price (WPCT)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Woodford Patient Capital Trust	LSE:WPCT	London	Ordinary Share	GB00BVG1CF25	ORD 1P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	-1.00p	-1.00%	99.00p	99.20p	99.75p	101.00p	99.00p	100.10p	1,048,934	16:35:16

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Equity Investment Instruments	1.3	-0.7	-0.1	-	818.73

Related Shares
Std Life Aber (SLA), Scottish Mortgage (SMT), Tiger Resource (TIR), Auctus Growth (AUCT)

Woodford Patient Capital (WPCT) Latest News (1)

Woodford Patient Capital News

Date	Time	Source	Headline
18/8/2017	10:26	UKREG	Woodford Patient Capital Trust PLC Net Asset Value(s)
17/8/2017	11:24	UKREG	Woodford Patient Capital Trust PLC Net Asset Value(s)
16/8/2017	10:58	UKREG	Woodford Patient Capital Trust PLC Net Asset Value(s)
15/8/2017	11:43	UKREG	Woodford Patient Capital Trust PLC Net Asset Value(s)
14/8/2017	10:39	UKREG	Woodford Patient Capital Trust PLC Net Asset Value(s)
11/8/2017	10:12	UKREG	Woodford Patient Capital Trust PLC Net Asset Value(s)
10/8/2017	11:31	UKREG	Woodford Patient Capital Trust PLC Net Asset Value(s)
09/8/2017	10:10	UKREG	Woodford Patient Capital Trust PLC Net Asset Value(s)
08/8/2017	10:31	UKREG	Woodford Patient Capital Trust PLC Net Asset Value(s)
07/8/2017	11:13	UKREG	Woodford Patient Capital Trust PLC Net Asset Value(s)

More Woodford Patient Capital News

Woodford Patient Capital Takeover Rumours

Woodford Patient Capital (WPCT) Share Charts

1 Year Woodford Patient Capital Chart

1 Month Woodford Patient Capital Chart

Intraday Woodford Patient Capital Chart

Woodford Patient Capital (WPCT) Discussions and Chat

Woodford Patient Capital Forums and Chat

Date	Time	Title	Posts
09/8/2017	21:20	Woodford Patient Capital Trust	103
09/8/2017	21:19	::: WOODFORD PATIENT CAPITAL TRUST :::	1,080

Add a New Thread

Woodford Patient Capital (WPCT) Most Recent Trades

No Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type

View all Woodford Patient Capital trades in real-time

Woodford Patient Capital (WPCT) Top Chat Posts

Date	Subject
20/8/2017 09:20	Woodford Patient Capital Daily Update: Woodford Patient Capital Trust is listed in the Equity Investment Instruments sector of the London Stock Exchange with ticker WPCT. The last closing price for Woodford Patient Capital was 100p. Woodford Patient Capital Trust has a 4 week average price of 99p and a 12 week average price of 90.60p. The 1 year high share price is 106.50p while the 1 year low share price is currently 86.15p. There are currently 827,000,000 shares in issue and the average daily traded volume is 872,528 shares. The market capitalisation of Woodford Patient Capital Trust is £818,730,000. Read Full Thread Reply
04/8/2017 12:24	mad foetus: What does "10 years of growth to achieve its existing valuation mean"? Where are these rules written down?I don't much like PURP, but it is a disruptive company, and all that matters is its share price and the willingness of the market to believe that it will be able to generate profits in future.Or to ask the question the other way around, at what time since it was launched would you have bought shares in Amazon? Or would you have stood by, saying it was overvalued, while it 100 bagged?The only rule in investing is to make money. Read Full Thread Follow Reply
20/7/2017 09:58	jonwig: mazarin - how the NAV is arrived at is here, From post #1013: There are strict rules for valuing unquoted companies: Http://www.privateequityvaluation.com/download/i/mark_dl/u/4012990401/4625734325/151222%20IPEV%20Valuation%20Guidelines%20December%202015%20Final.pdf Valuation guidelines, p11. I don't see the point of spending money on a daily NAV when so much of the portfolio is unquoted. As for how the share price is determined, it's quite simply supply and demand with trades going through market makers. I suspect there will soon be selling by frustrated holders who bought in the 2015 gold rush and want rid. If I actually knew what moved share prices, I'd be rather richer than I am. EDIT: it's actually traded on SETS too, though not many participants it seems. Read Full Thread Follow Reply
20/7/2017 09:33	wtacraig1: Prefer to see the share price rise supported by an eqiuvalent rise in the NAV. Danger is that this increase is froth and demand created by hype. No doubt the natural balance will reestablish itself in due course. Read Full Thread Follow Reply
30/4/2017 20:18	topvest: I think its the wrong time in the economic cycle to be buying this trust. This stock (as all the US tech bubble stocks) will get hammered when the next downturn comes. Best time to buy this is at an equivalent time to March 2009, albeit hopefully nothing as deep as the last recession. What struck me in the latest annual report is the £75m overdraft. This is a strategic error in my book as such debt is only really advisable when you have a liquid portfolio. Lets say that the share price drops 50% on a stock market bear phase. If NAV drops to 60p and share price to 45p they are going to be forced sellers on their illiquid portfolio to avoid a covenant issue. That would be a disaster. Why take that risk at this point in the cycle? Its also pretty obvious that the premium has turned to a discount and now that discount is widening. This phase has not finished. The trust has a good long-term model but its the wrong time...10 years into an economic recovery, a widening discount on poor performance and a very imprudent bank overdraft. I will keep on my watch list. Read Full Thread Follow Reply
23/2/2017 11:25	woodpecker25: On a positive note... Purplebricks up over 15% today following £50mil placing this morning. Share Price has almost doubled in 3 months. WIM holds 29% of PURP. Read Full Thread Follow Reply
07/1/2017 14:43	jonwig: topvest - you could be right. I think the NAV will be less volatile than the market due to valuation rules. But the share price could well fall if the market does. Hence the discount widens. Lack of a dividend makes it less attractive, and I suppose there's still the background aim to issue more shares. Read Full Thread Follow Reply
07/1/2017 10:17	jonwig: Citywire has an article noting that WPCT is now at its cheapest, relative to NAV: Woodford Patient Capital Trust might be worth a look for anyone who didn’t join its £800 million record flotation in 2015. Neil Woodford’s trust has so far disappointed investors like me who leaped at the chance to back the star manager’s passion for early stage medical and technology stocks. After an early rally the stock slid back and at just under 90p is still a long way off its 100p launch price. However, the shares have rallied from a post-Brexit low of 81p, helped in part by the revival in healthcare and biotech prompted by the election of Donald Trump. Nevertheless, its share price gain has not fully reflected the advance in the net asset value of the underlying portfolio, the result being the discount has widened to 6%, close to the low reached after the EU referendum vote. It then goes on to analyse Z-scores of various trusts: Http://citywire.co.uk/money/investment-trust-watch-buy-woodford-sell-alliance/a982332?ref=citywire-money-highlights-of-the-week-list Read Full Thread Follow Reply
14/3/2016 14:25	dr biotech: I am pretty sure that he has all his money invested in either the WPCT or his equity funds. He is doing a live webcast as I type. NEIL WOODFORD says: Today 2:00 pm Kelvin (and others that have asked similar questions), The weakness of the WPCT share price and NAV since the start of 2016 has been the product of the pretty severe sell-off in shares across healthcare, biotech and early-stage quoted stocks, both here in the UK and in the US. Much of this, we believe to be driven by short-term positioning and rotational activity amongst the fund management community. We don’t believe that it is driven by a correction of over-valuation, nor by a deterioration in fundamentals. We remain very pleased with the underlying progress of the businesses in which we have invested in the trust. Indeed, in what has been a pretty short space of time since launch, our expectations for the underlying performance of many businesses in the portfolio have been exceeded. This is a long-term vehicle. We hope to deliver good performance in the short-term but believe we should be judged over the 3 to 5 year time scale we have talked about consistently since launch. Kind regards Neil Read Full Thread Follow Reply
17/2/2016 09:08	liquidkid: Don't want to have to put out another downer, but you just can't ignore that this is happening on a inexcusable level of regularity. And now for the Clanger of the week: Oxford-based e-Therapeutics' (ETX) most advanced drug flopped badly in a Phase IIb study for depression, beaten out on efficacy by an aging generic generiatric. Is The latest in a long lineup of companies to try a new strategy in combating depression and fail at it. Alkermes (ALKS) recently attempted its own pivotal study using a new study design that randomized nonresponders in the initial placebo group only to concede failure just weeks ago. This observation sums it up nicely Mach100 15 Feb'16 (ETX) Not an investor here but have seen a few presentations at Mayfair. They looked interesting at that time. Today's RNS seems weird to me. It seemed to be presented as good news when it is probably anything but. A massive drop first thing and any bottom feeders would have done well. I can't see given the wooliness of the RNS any great upside on this so I confess I am slightly bemused by the share price partial recovery since the opening. - The share price movement has all the hallmarks of Woofordunnit Meddling. Read Full Thread Follow Reply
18/1/2016 12:48	jonwig: If he's looking to raise new equity, his options are getting a bit limited. Ideally, he would like a substantial share price premium so that he can tuck the offer price between nav and share price His other option would be to to offer "C" shares at, say, 100p, and when these are fully invested have them convert on the basis of nav ratios. But this would fail to attract if the existing ords fell to a discount. His quoted holdings will carry a market valuation, but has he adjusted unquoteds at all? Read Full Thread Follow Reply

Woodford Patient Capital share price data is direct from the London Stock Exchange

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P:31 V: D:20170820 10:00:03